|
|
Key Sub-Saharan African Infectious Disease Pharmaceutical MarketsPublished by: Frost & Sullivan Published: Feb. 25, 2008 - 224 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled Infectious Disease Pharmaceutical Markets in Key Sub-Saharan African Countries provides market sizes and growth forecasts for the period 2006 to 2012 as well as market trends. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: HIV, TB and Malaria.This analysis is available through our Pharmaceuticals and Biotechnology Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Market Overview International Funding Coupled with Large Target Population Promote Uptake of Infectious Disease Pharmaceuticals Infectious diseases are responsible for over 300 million illnesses and 5 million deaths worldwide. Sub-Saharan African countries account for almost 90 per cent of these cases with HIV, TB and Malaria being the leading causes of death. The number of patients being treated for these ailments is expected to double in the next five years. Consequently, billions of dollars are being pumped into the region from international funding organisations with the bulk of the funds being channelled towards the purchase of pharmaceutical products. International donor organisations have committed to provide support for the expansion of HIV and malaria treatment programmes in Kenya, Tanzania and Nigeria. Such increases in donor funding are acting as key drivers in the market’s growth. "The infectious disease pharmaceuticals market in Nigeria, Kenya and Tanzania is firmly in the growth stage," states the analyst of this research. "This is a result not only of government expansion of treatment programmes, but also due to a general increase in demand related to improving economic conditions." Also, despite high levels of poverty and the subsequent market price sensitivity, the region has a large and growing population that is increasingly able to pay for enhanced health services and pharmaceutical products. This expanding population pool provides a suitable base for the distribution of substantial volumes of infectious disease pharmaceuticals. Promising Market Emerges for Generics "Currently, only 40 per cent of the region’s demand for pharmaceutical products for HIV, Malaria and TB is met by local production," comments the analyst of this research. "The price-sensitive nature of the sub-Saharan African pharmaceutical market creates a demand for cheaper generic products which a larger proportion of the population are able to afford." Most governments use price as a key selection criteria for the award of tenders. Therefore, the general preference for low cost products, by both government and private sector end-users is boosting the demand for generic pharmaceuticals. In addition, governments and the public prefer locally produced goods. Multi-national companies will thus gain a competitive advantage if they choose to manufacture their products locally. It will also be beneficial to set up plants or distribution points in regional economic hubs, such as Kenya and/or Nigeria. These can then be used as focal points for distribution into surrounding countries. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||